Sanders Capital’s AbbVie ABBV Stock Holding History

Sanders Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122M	Sell	483,963 -32,630	-6%	-$7.02M	0.12%	39
2026 Q1	$112M	Sell	516,593 -15,570	-3%	-$3.45M	0.13%	37
2025 Q4	$122M	Sell	532,163 -16,160	-3%	-$3.68M	0.14%	38
2025 Q3	$127M	Sell	548,323 -820	-0.1%	-$167K	0.16%	40
2025 Q2	$102M	Buy	549,143 +380	+0.1%	+$70.6K	0.14%	40
2025 Q1	$115M	Sell	548,763 -3,760	-0.7%	-$731K	0.17%	39
2024 Q4	$98.2M	Sell	552,523 -930	-0.2%	-$171K	0.14%	38
2024 Q3	$109M	Sell	553,453 -1,395	-0.3%	-$260K	0.16%	37
2024 Q2	$95.2M	Sell	554,848 -260	-0%	-$43.1K	0.15%	36
2024 Q1	$101M	Sell	555,108 -50	-0%	-$8.62K	0.17%	33
2023 Q4	$86M	Sell	555,158 -300	-0.1%	-$43.7K	0.16%	33
2023 Q3	$82.8M	Buy	555,458 +350	+0.1%	+$51.4K	0.18%	34
2023 Q2	$74.8M	Sell	555,108 -29,190	-5%	-$4.28M	0.16%	37
2023 Q1	$93.1M	Buy	584,298 +1,530	+0.3%	+$234K	0.22%	33
2022 Q4	$94.2M	Sell	582,768 -4,510	-0.8%	-$692K	0.25%	31
2022 Q3	$78.8M	Sell	587,278 -1,640	-0.3%	-$235K	0.22%	30
2022 Q2	$90.2M	Sell	588,918 -1,770	-0.3%	-$270K	0.23%	30
2022 Q1	$95.8M	Sell	590,688 -1,580	-0.3%	-$230K	0.21%	31
2021 Q4	$80.2M	Buy	592,268 +2,750	+0.5%	+$325K	0.16%	33
2021 Q3	$63.6M	Sell	589,518 -2,500	-0.4%	-$286K	0.14%	35
2021 Q2	$66.7M	Buy	592,018 +60	+0%	+$6.76K	0.15%	33
2021 Q1	$64.1M	Sell	591,958 -2,700	-0.5%	-$289K	0.15%	33
2020 Q4	$63.7M	Sell	594,658 -75,900	-11%	-$7.29M	0.17%	33
2020 Q3	$58.7M	Sell	670,558 -29,965	-4%	-$2.82M	0.2%	33
2020 Q2	$68.8M	Sell	700,523 -15,300	-2%	-$1.35M	0.26%	31
2020 Q1	$54.5M	Sell	715,823 -22,500	-3%	-$1.92M	0.26%	32
2019 Q4	$65.4M	Buy	738,323 +116,590	+19%	+$9.68M	0.23%	37
2019 Q3	$47.1M	Hold	621,733	–	–	0.21%	35
2019 Q2	$45.2M	Buy	621,733 +500	+0.1%	+$39.3K	0.21%	36
2019 Q1	$50.1M	Sell	621,233 -200	-0%	-$16.4K	0.24%	37
2018 Q4	$57.3M	Hold	621,433	–	–	0.32%	37
2018 Q3	$58.8M	Sell	621,433 -1,900	-0.3%	-$180K	0.3%	37
2018 Q2	$57.8M	Sell	623,333 -1,800	-0.3%	-$176K	0.31%	34
2018 Q1	$59.2M	Sell	625,133 -1,000	-0.2%	-$110K	0.33%	32
2017 Q4	$60.6M	Sell	626,133 -1,400	-0.2%	-$132K	0.33%	34
2017 Q3	$55.8M	Hold	627,533	–	–	0.34%	34
2017 Q2	$45.5M	Buy	627,533 +4,400	+0.7%	+$296K	0.29%	34
2017 Q1	$40.6M	Sell	623,133 -200	-0%	-$12.6K	0.27%	35
2016 Q4	$39M	Sell	623,333 -4,100	-0.7%	-$250K	0.28%	36
2016 Q3	$39.6M	Sell	627,433 -600	-0.1%	-$38.8K	0.31%	36
2016 Q2	$38.9M	Buy	628,033 +2,504	+0.4%	+$153K	0.32%	39
2016 Q1	$35.7M	Hold	625,529	–	–	0.31%	40
2015 Q4	$37.1M	Sell	625,529 -17,994	-3%	-$1.04M	0.34%	41
2015 Q3	$35M	Sell	643,523 -9,100	-1%	-$592K	0.35%	39
2015 Q2	$43.9M	Sell	652,623 -115,200	-15%	-$7.52M	0.41%	39
2015 Q1	$44.9M	Sell	767,823 -11,162	-1%	-$674K	0.44%	39
2014 Q4	$51M	Buy	778,985 +2,200	+0.3%	+$139K	0.5%	37
2014 Q3	$44.9M	Hold	776,785	–	–	0.48%	40
2014 Q2	$43.8M	Hold	776,785	–	–	0.49%	39
2014 Q1	$39.9M	Sell	776,785 -5,354	-0.7%	-$271K	0.46%	41
2013 Q4	$41.3M	Sell	782,139 -1,700	-0.2%	-$83.6K	0.49%	38
2013 Q3	$35.1M	Hold	783,839	–	–	0.48%	36
2013 Q2	$32.4M	Buy	+783,839	New	+$34.3M	0.44%	37

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sanders Capital's ABBV Position: Q2 2026 in Review

Sanders Capital reduced its AbbVie (ABBV) stake by 6.3% in Q2 2026, selling an estimated $7.02M and leaving 483,963 shares worth $122M. The position accounts for 0.12% of the portfolio, ranked #39.

Sanders Capital first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $127M in Q3 2025. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sanders Capital held 483,963 shares of AbbVie worth $122M as of Q2 2026.
Sanders Capital sold 32,630 AbbVie shares in Q2 2026, an estimated $7.02M.
AbbVie made up 0.12% of Sanders Capital's portfolio in Q2 2026, its #39 holding.
Sanders Capital first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Sanders Capital's AbbVie position peaked at $127M in Q3 2025.
4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sanders Capital's 13F filing for Q2 2026, filed 10 Aug 2026.